HIM
PTGX icon

Hillsdale Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Hillsdale Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-170
Closed -$5.89K – 684
2024
Q2 		$5.89K Sell
170
-30
-15% -$879 ﹤0.01% 543
2024
Q1 		$5.79K Buy
+200
New +$5.44K ﹤0.01% 558
2021
Q1 		– Sell
-41,500
Closed -$837K – 653
2020
Q4 		$837K Buy
+41,500
New +$893K 0.08% 253

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's PTGX Position: Q3 2024 in Review

Hillsdale Investment Management sold out of Protagonist Therapeutics (PTGX) in Q3 2024, closing a stake of 170 shares — an estimated $5.89K sold.

Hillsdale Investment Management first reported a position in PTGX in Q4 2020 and held it in 3 quarters. The position peaked at $837K in Q4 2020. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Hillsdale Investment Management reported no remaining Protagonist Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 170 Protagonist Therapeutics shares in Q3 2024, an estimated $5.89K.
  • Hillsdale Investment Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 3 quarters.
  • Hillsdale Investment Management's Protagonist Therapeutics position peaked at $837K in Q4 2020.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Hillsdale Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.